Icad

ICAD55

Penny Stock

$1.64arrow_drop_down8.12%-$0.14

Penny Stock

ICAD55

$1.64

arrow_drop_down8.12%-$0.14

Penny Stock

Performance History

Key Stats
Open	$1.77
Prev. Close	$1.78
EPS	-0.15
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$43.22M
PE Ratio	-

	LOW	HIGH
Day Range	1.64	1.81
52 Week Range	1.18	2.99

Ratios







EPS	-0.15

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Icad (ICAD)

Icad Inc (ICAD) is a company that specializes in the development and sale of advanced cancer detection and therapy solutions. With a focus on image analysis technology, Icad provides innovative solutions that help physicians detect and treat cancer more effectively. The company's products include computer-aided detection software, therapeutic radiation devices, and quality assurance solutions. Icad's advanced technologies have been widely adopted by leading healthcare institutions around the world.

Icad Inc's stock price history shows a steady growth trend over the years. The company's stock has experienced both ups and downs, but overall, it has shown resilience and an upward trajectory. Investors who have held onto their ICAD shares have been rewarded with consistent gains in recent years. With a strong market presence and a robust product portfolio, Icad Inc is well-positioned to continue its growth in the coming years.

Websitecall_made

Sector: Healthcare
Industry: Medical Devices
CEO: Ms. Dana R. Brown
Headquarters: Nashua
Employees: 108
Exchange: NASDAQ

Keep an eye on Icad

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Icad 's (ICAD) price per share?

The current price per share for Icad (ICAD) is $1.64. The stock has seen a price change of -$0.15 recently, indicating a -8.12% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Icad (ICAD)?

For Icad (ICAD), the 52-week high is $3, which is 82.87% from the current price. The 52-week low is $1.18, the current price is 38.98% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Icad (ICAD) a growth stock?

Icad (ICAD) has shown an average price growth of -6.65% over the past three years. It has received a score of 15 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Icad as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Icad (ICAD) stock price performance year to date (YTD)?

As of the latest data, Icad (ICAD) has a year-to-date price change of -10.87%. Over the past month, the stock has experienced a price change of -15.9%. Over the last three months, the change has been -5.75%. Over the past six months, the figure is -6.29%. Looking at a longer horizon, the five-year price change stands at -75.19%.

help

Is Icad (ICAD) a profitable company?

Icad (ICAD) has a net income of -$4.85M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 83.94% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -38.74% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $17.32M, although specific revenue growth data is currently not available. The gross profit is $14.54M. Operating income is noted at -$7.69M. Furthermore, the EBITDA is -$4.69M.

help

What is the market capitalization of Icad (ICAD)?

Icad (ICAD) has a market capitalization of $43.22M. The average daily trading volume is 1.7, indicating the stock's liquidity and investor engagement.

News

iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference

ICAD

PROFOUND CLOUD

AI-POWERED CANCER DETECTION

INTERNATIONAL EXPANSION

Oct 3, 2024

iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024

COMPUTER AIDED DETECTION

Computer Aided Detection (CAD) - Global Strategic Business Report to 2030: Increasing Prevalence of Cancer Driving Growth, Increasing Demand for Automated Detection

CALENDAR OF EVENTS

Jun 26, 2024

iCAD to Highlight Promising Research on Potential of its AI Algorithm to More Accurately Identify and Personalize Breast Cancer Risk at SIIM 2024

CALENDAR OF EVENTS

HEALTH

Jun 4, 2024

iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference

CALENDAR OF EVENTS

CONFERENCE CALLS/ WEBCASTS

May 8, 2024

UPDATE - iCAD to Report First Quarter 2024 Financial Results on May 15, 2024